Page 2 of 2 Previous

Continued: Sleep apnea trials favor Maple Grove firm's pacemaker-like device

  • Article by: JAMES WALSH , Star Tribune
  • Last update: January 9, 2014 - 6:00 AM

What’s ahead?

Inspire’s device has been approved for sale in Europe and has limited availability there, but still needs U.S. Food and Drug Administration approval for sale in this country. An advisory panel is scheduled to meet Feb. 20 and could make a recommendation.

Suraj Kalia, an analyst with Northland Securities, said Inspire “is not on the radar screen for the majority of investors.” He expects that to change with FDA approval, which could happen before the end of this year.

While the Inspire technology is more expensive than CPAP — up to an estimated $30,000, including surgical and recovery costs, vs. $1,000 for a CPAP — Kalia said the possibility of savings down the road by reducing apnea-related health costs makes it “compelling.”

“For a company like Inspire, they are starting from ground zero,” Kalia said. “I could see them easily growing to $200 million-plus in revenues very quickly.”


James Walsh • 612-673-7428

  • related content

  • Inspire Medical Systems' pacemaker-like device sends electric pulses to nerves in the tongue to control sleep apnea.

  • get related content delivered to your inbox

  • manage my email subscriptions


Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters


Golden Gavel by Star Tribune

Countdown to great deals

Bid Sept. 21-29